Journal Watch · Cell · 2026

Long-term reversal of Duchenne muscular dystrophy via circular arRNA-guided exon skipping in monkeys and humans.

Together, consistent dystrophin restoration across DMD NHP models, patient-derived cardiomyocytes, and treated patients highlights the translational potential of circ-arRNA-mediated exon skipping as a therapeutic strategy for DMD.

Guo W, Tang H, Yi Z et al.Cell3 min readPharma relevance 85/100

DOI: 10.1016/j.cell.2026.05.030PMID: 42269605Study type: clinical study

TL;DR

Together, consistent dystrophin restoration across DMD NHP models, patient-derived cardiomyocytes, and treated patients highlights the translational potential of circ-arRNA-mediated exon skipping as a therapeutic strategy for DMD.

Key findings

  • In a first-in-human study, a single dose of adeno-associated virus (AAV)-delivered circ-arRNA produced safe, dose-dependent exon skipping in three patients, accompanied by measurable gains in motor and cardiopulmonary function.
  • Together, consistent dystrophin restoration across DMD NHP models, patient-derived cardiomyocytes, and treated patients highlights the translational potential of circ-arRNA-mediated exon skipping as a therapeutic strategy for DMD.

What they did

By engaging key splicing elements, circ-arRNAs bypass out-of-frame DMD mutations and restore dystrophin expression through ADAR-dependent and ADAR-independent mechanisms. In DMD nonhuman primates (NHPs) carrying hotspot mutations, a single administration achieved durable dystrophin restoration and sustained motor improvement for at least 1.5 years without eliciting anti-dystrophin immune responses.

Full abstract (original)

Background: Duchenne muscular dystrophy (DMD) is a fatal neuromuscular disorder caused by mutations in the DMD gene, leading to progressive muscle degeneration, loss of mobility, and premature death. Here, we applied leverage endogenous adenosine deaminase acting on RNA (ADAR) for programmable editing of RNA (LEAPER) 2.0, an RNA editing platform, to achieve exon skipping by harnessing endogenous ADAR through circular ADAR-recruiting RNAs (circ-arRNAs).

What they did: By engaging key splicing elements, circ-arRNAs bypass out-of-frame DMD mutations and restore dystrophin expression through ADAR-dependent and ADAR-independent mechanisms. In DMD nonhuman primates (NHPs) carrying hotspot mutations, a single administration achieved durable dystrophin restoration and sustained motor improvement for at least 1.5 years without eliciting anti-dystrophin immune responses.

Results & conclusions: In a first-in-human study, a single dose of adeno-associated virus (AAV)-delivered circ-arRNA produced safe, dose-dependent exon skipping in three patients, accompanied by measurable gains in motor and cardiopulmonary function. Together, consistent dystrophin restoration across DMD NHP models, patient-derived cardiomyocytes, and treated patients highlights the translational potential of circ-arRNA-mediated exon skipping as a therapeutic strategy for DMD.

Abstract © the authors / Cell (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/j.cell.2026.05.030 · PubMed 42269605.

Why it matters for pharma & biotech

  • Directly relevant to teams in gene therapy — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: gene therapy

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Cell study find?

Together, consistent dystrophin restoration across DMD NHP models, patient-derived cardiomyocytes, and treated patients highlights the translational potential of circ-arRNA-mediated exon skipping as a therapeutic strategy for DMD.

What type of study is this?

It is a clinical study, published in Cell in 2026. By engaging key splicing elements, circ-arRNAs bypass out-of-frame DMD mutations and restore dystrophin expression through ADAR-dependent and ADAR-independent mechanisms.

Where can I read the original paper?

The original is at the publisher via DOI 10.1016/j.cell.2026.05.030. PubMed ID: 42269605. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Guo W, Tang H, Yi Z et al.. Long-term reversal of Duchenne muscular dystrophy via circular arRNA-guided exon skipping in monkeys and humans.. Cell (2026). DOI: 10.1016/j.cell.2026.05.030.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/long-term-reversal-of-duchenne-muscular-dystrophy-via-circular-arrna-gui-605030/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides